Financial Performance - Total revenue for Q4 2024 is estimated to be in the range of $5.0 million to $5.1 million, a record for the company, compared to $4.8 million in Q4 2023[9] - The company used an estimated $1.5 million of net cash in operations for Q4 2024, compared to $1.6 million for the same period in 2023[9] Cash Position - Estimated cash as of December 31, 2024, was $6.5 million, down from $8.6 million as of December 31, 2023[9]

Core Viewpoint - Ekso Bionics Holdings, Inc. reported record revenue for the fourth quarter of 2024, with a focus on expanding patient access and increasing demand for its exoskeleton devices [2][11]. Summary of Fourth Quarter 2024 Financial Results - The company recorded revenue of $5.1 million for Q4 2024, a 5% increase from $4.8 million in Q4 2023 [3]. - Gross profit for Q4 2024 was $2.7 million, up 15% from the previous year, resulting in a gross margin of approximately 53%, compared to 49% in Q4 2023 [4]. - Sales and marketing expenses decreased to $1.9 million from $2.0 million in Q4 2023, attributed to lower headcount and discretionary payroll [5]. - Research and development expenses for Q4 2024 were $845,000, down from $1.3 million in Q4 2023, due to reduced discretionary payroll and consultant costs [5]. - General and administrative expenses fell to $2.2 million from $2.5 million in Q4 2023, primarily due to lower discretionary payroll [6]. - The net loss for Q4 2024 was $3.4 million, or $0.14 per share, compared to a net loss of $3.2 million, or $0.22 per share, in Q4 2023 [6]. Summary of Full Year 2024 Financial Results - For the full year 2024, the company reported revenue of $17.9 million, a 2% decrease from $18.3 million in 2023 [8]. - Gross profit for the full year was $9.5 million, with a gross margin of approximately 53%, compared to $9.1 million and a 50% margin in 2023 [9]. - Sales and marketing expenses for the full year decreased to $7.3 million from $8.5 million in 2023 [10]. - Research and development expenses for the full year were $3.9 million, down from $5.0 million in 2023 [12]. - General and administrative expenses for the full year were $8.8 million, compared to $10.7 million in 2023 [13]. - The net loss for the full year was $11.3 million, or $0.56 per share, a 25% improvement from a net loss of $15.2 million, or $1.10 per share, in 2023 [13]. - The company used $9.8 million of net cash in operations for the full year, down from $12.1 million in 2023 [14]. Additional Highlights - The company named National Seating & Mobility as its exclusive distributor for the Ekso Indego Personal device in the U.S. complex rehabilitation technology industry [11]. - As of December 31, 2024, the company had cash and restricted cash of $6.5 million [14].

Core Insights - Ekso Bionics Holdings, Inc. will release its financial and business results for Q4 and full year 2024 on March 3, 2025, after market close [1] - A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and recent business developments [1] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility for both medical and industrial applications [3] - The company was founded in 2005 and is recognized for its innovative wearable robots, which assist individuals with paralysis and enhance capabilities in various job sites [3] - Ekso Bionics is headquartered in the San Francisco Bay Area and is publicly traded on the Nasdaq under the symbol "EKSO" [3]

Core Viewpoint - Ekso Bionics has partnered with National Seating & Mobility to enhance the distribution of its Ekso Indego Personal exoskeleton device, aiming to improve access for individuals with spinal cord injuries and mobility challenges across the United States [1][3]. Company Overview - Ekso Bionics is a leader in exoskeleton technology, focusing on medical and industrial applications, and is known for its innovative wearable robots that enhance human mobility [4]. - The company was founded in 2005 and is headquartered in the San Francisco Bay Area, listed on the Nasdaq under the symbol "EKSO" [4]. Product Details - The Ekso Indego Personal is a lightweight, portable lower extremity powered exoskeleton designed to help individuals with spinal cord injuries stand and walk independently [2]. - It features a modular quick connect design, allowing users to don and doff the device without assistance, and includes an advanced gait mode that enables faster walking speeds [2]. Partnership Significance - The partnership with NSM is expected to leverage NSM's extensive experience in complex rehabilitation technology and its network of insurance partners to broaden access to the Ekso Indego Personal device [3]. - NSM operates over 180 locations across the U.S. and Canada and has been providing mobility solutions for over 30 years, supporting more than 250,000 mobility solutions annually [5].

Core Insights - Ekso Bionics Holdings, Inc. anticipates record revenues for Q4 2024, estimating total revenue between $5.0 million and $5.1 million, compared to $4.8 million in Q4 2023 [2] - The company has made significant progress in 2024, including initial CMS reimbursement for the Ekso Indego Personal device, which is expected to enhance access for Medicare-covered patients [3] - As of December 31, 2024, estimated cash was $6.5 million, down from $8.6 million a year earlier, with an estimated net cash usage of $1.5 million in operations for Q4 2024 [3] Financial Performance - Total revenue for Q4 2024 is projected to be a record at $5.0 million to $5.1 million, marking an increase from $4.8 million in Q4 2023 [2] - Estimated cash as of December 31, 2024, was $6.5 million, a decrease from $8.6 million at the end of 2023 [3] - The company used approximately $1.5 million of net cash in operations during Q4 2024, slightly less than the $1.6 million used in the same period of 2023 [3] Strategic Developments - The company is focused on expanding its CMS claim pipeline and increasing demand for its flagship EksoNR device as part of its long-term growth strategy [3] - Ekso Bionics is recognized as a leading developer of exoskeleton solutions, enhancing human capabilities in both medical and industrial applications [5]

Core Viewpoint - Ekso Bionics Holdings, Inc. is at the forefront of exoskeleton technology, focusing on its applications in medical rehabilitation and industrial use, and is participating in an upcoming webinar to discuss advancements in this field [1][2]. Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility across various applications [4]. - The company was founded in 2005 and is headquartered in the San Francisco Bay Area, listed on the Nasdaq under the symbol "EKSO" [4]. - Ekso Bionics is recognized for its innovative wearable robots, which assist individuals with paralysis and enhance capabilities in industrial settings [4]. Webinar Details - The upcoming webinar titled "AI-powered Exoskeletons Revolutionizing Rehabilitation and Mobility" is scheduled for November 19 at 10:00 a.m. ET [2]. - The session will cover the latest advancements in exoskeleton technology and its role in medical rehabilitation, highlighting the challenges and opportunities in the field [2]. Key Personnel - Katherine Strausser, a Principal Controls Engineer at Ekso Bionics, will be participating in the webinar [1]. - She holds a Ph.D. in Mechanical Engineering and has significant expertise in robotics and human-exoskeleton interaction, being one of the original inventors of the EksoNR device [3].

Company Overview - Ekso Bionics Holdings, Inc. is a leader in exoskeleton technology for both medical and industrial applications [3] - The company was founded in 2005 and is headquartered in the San Francisco Bay Area [3] - Ekso Bionics is publicly traded on the Nasdaq Capital Market under the symbol "EKSO" [3] Recent Developments - The CEO Scott Davis and CFO Jerome Wong will participate in the 15th Annual Craig-Hallum Alpha Select Conference in New York on November 19, 2024 [1] - Management will also engage in one-on-one meetings with institutional investors during the conference [2] Product and Technology - Ekso Bionics develops exoskeleton solutions that enhance human strength, endurance, and mobility [3] - The company offers technologies that assist individuals with paralysis to stand and walk, as well as enhance capabilities in various job sites globally [3]

Company Performance - Ekso Bionics reported a quarterly loss of $0.10 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.08, and an improvement from a loss of $0.24 per share a year ago, indicating a surprise of -25% [1] - The company posted revenues of $4.13 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 31.21%, and down from $4.61 million in the same quarter last year [2] - Over the last four quarters, Ekso Bionics has not surpassed consensus EPS estimates and has topped revenue estimates only once [2] Stock Performance - Ekso Bionics shares have declined approximately 58.4% since the beginning of the year, contrasting with the S&P 500's gain of 21.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $6.42 million, and for the current fiscal year, it is -$0.42 on revenues of $21.13 million [7] Industry Outlook - The Medical - Instruments industry, to which Ekso Bionics belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Financial Data and Key Metrics - Quarterly sales for Q3 2024 were $4.1 million, down from $4.6 million in Q3 2023 [20] - Gross profit for Q3 2024 was $2.2 million, with a gross margin of 53.5%, slightly up from 53.3% in Q3 2023 [20] - Net loss for Q3 2024 decreased to $2.1 million ($0.10 per share) from $3.4 million ($0.24 per share) in Q3 2023 [21] - Revenue for the first nine months of 2024 was $12.8 million, down from $13.4 million in the same period in 2023 [22] - Net loss for the first nine months of 2024 was $7.9 million ($0.42 per share), compared to $12 million ($0.88 per share) in the same period in 2023 [23] - Cash and restricted cash as of September 30, 2024, was $8.3 million, down from $8.6 million at the end of 2023 [24] Business Line Data and Key Metrics - 33 EksoHealth devices were sold in Q3 2024, with approximately half of the placements in Europe and several in APAC [25] - 28% of Q3 revenue was attributed to the personal product line [25] - EksoNR devices are deployed in 9 of the top 10 rehabilitation centers in the US, indicating a growing standard-of-care adoption [13] - Sales of EksoWorks' EVO exoskeleton were impacted by labor strikes in US manufacturing industries [15] Market Data and Key Metrics - European sales achieved record levels in Q3 2024, driven by strong demand in neurorehabilitation centers [14] - US sales were affected by procurement cycle fluctuations and delayed capital purchases by customers into Q4 2024 and early 2025 [12] - The company expanded its international distribution network, achieving greater operating leverage in foreign markets [15] Company Strategy and Industry Competition - The company is focused on expanding access to its Ekso Indego Personal technology, particularly after CMS approval and reimbursement for Medicare and Medicaid patients [8][11] - The company is leveraging its strong reputation in neurorehabilitation to drive growth for both EksoNR and Ekso Indego therapy devices [14] - The company is committed to developing relationships with IDNs to secure larger multi-unit capital contracts across North America [15] - The company is raising awareness about the benefits of its EVO exoskeleton in industries such as automotive, aerospace, construction, and renewable energy [16] Management Commentary on Operating Environment and Future Outlook - The company is optimistic about future prospects, with a growing pipeline of potential deals and a strong demand for its products [15][18] - The company expects procurement cycles with IDNs to normalize in the near term, which will positively impact sales in 2025 [30] - The company is working on expanding indications for its Indego family of products through clinical studies, leveraging relationships with top neurological research hospitals [36][37] Other Important Information - The company closed an underwritten public offering in September 2024, resulting in net proceeds of approximately $5 million [24] - The company has a total product portfolio with a potential addressable market exceeding $13 billion across the continuum of care [18] Q&A Session Summary Question: Geographic distribution of device placements - Approximately half of the 33 placements in Q3 2024 were in Europe, with several in APAC, and the majority outside the US [25] Question: Status of CMS claims and reimbursement - Multiple claims have been submitted year-to-date, with one claim reimbursed and two requiring additional information for resubmittal [27] - The reimbursement process for claims is taking longer than expected [28] Question: Backlog and procurement cycles - The company has a strong backlog for Q4 2024, with demand in Europe remaining strong and North America expected to see a positive impact from renewal cycles in 2025 [30] Question: Impact of CMS reimbursement on IDN purchasing - The delay in IDN purchases is more related to macroeconomic uncertainties and procurement cycles rather than distraction from CMS reimbursement [32] Question: Outlook for European sales in Q4 2024 - Demand in Europe remains strong, with a solid backlog entering Q4, indicating another strong quarter [33][35] Question: Expansion into neurological conditions - The company is working on clinical studies to expand indications for its Indego family of products, leveraging relationships with top neurological research hospitals [36][37] Question: Revenue breakdown for personal products - Approximately 20% of total revenue in Q3 2024 was attributed to personal products [38]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-036 ...